Robotic vs Open Prostatectomy: Outcomes and Recovery

Research-informed explainer — last updated April 12, 2026

Robotic and open prostatectomy remove the prostate through different surgical approaches, but long-term cancer control is comparable between them. Where the two diverge most is recovery: robotic surgery consistently shows less blood loss, shorter hospital stays, and faster return to urinary control. The choice between them ultimately comes down to your surgeon's training, your anatomy, and what matters most to you in recovery.

This explainer draws on research from three urologic oncologists in the Convene directory. Peter Carroll at UCSF published on prostate cancer taxonomy and treatment patterns across the national CaPSURE registry. Adam Kibel at Brigham and Women's Hospital co-authored the AUA guideline on castration-resistant prostate cancer and large-scale genetic analyses of prostate cancer risk. William Aronson at UCLA contributed to both phases of the landmark PIVOT trial, which directly compared radical prostatectomy to observation in men with localized prostate cancer.

What's the difference?

Radical prostatectomy is surgery to remove the entire prostate gland, typically performed for localized prostate cancer. Open retropubic radical prostatectomy (RRP) uses a single incision from the navel to the pubic bone. The surgeon works directly through that opening, with full tactile feedback and a direct view of the operative field.

Robot-assisted radical prostatectomy (RARP) uses several small incisions. The surgeon sits at a console a few feet away, controlling robotic arms that hold a camera and instruments. The three-dimensional magnified view and wrist-like instrument movement allow precise dissection in a confined space — particularly around the neurovascular bundles that control erections and the urinary sphincter that controls continence.

Both approaches aim to remove the prostate with clear margins while preserving as much function as possible. Differences in how each achieves that goal explain most of the outcome differences patients see.

At a glance

Recovery and functional outcomes

The most consistent finding across studies comparing robotic to open prostatectomy is that robotic surgery reduces blood loss and speeds early recovery. Patients undergoing RARP typically leave the hospital within one to two days rather than two to four days for open surgery, and catheter time is often shorter.

Continence recovery is where the evidence is clearest. A systematic review and meta-analysis published in European Urology, cited in research by Peter Carroll's group, examined studies on urinary continence recovery after RARP [2]. The analysis found a statistically significant advantage for robotic over open surgery at 12 months — men undergoing RARP were more likely to be continent (OR 1.53 versus open, p=0.03). At 12 months, continence rates in the studies ranged from 69% to 96% depending on how continence was defined and how the procedure was performed. Patient factors — age, prostate volume, baseline urinary function — were among the strongest predictors of outcome, independent of surgical approach.

Erectile function recovery is less clearly differentiated between approaches. Both rely on nerve-sparing technique. The robotic platform's magnification and precision may help with nerve identification, but whether that translates to better erection rates at two or three years is not consistently demonstrated across studies. What matters most is whether a nerve-sparing procedure was technically feasible for your tumor, and whether the surgeon performing your case does high volumes of nerve-sparing prostatectomy regardless of platform.

What the PIVOT trial found about surgery overall

Understanding whether prostatectomy is the right choice at all — before comparing techniques — is worth addressing. The PIVOT trial, a randomized controlled study co-authored by William Aronson and colleagues, enrolled 731 men with localized prostate cancer and randomized them to radical prostatectomy versus watchful waiting [8]. After 12 years of follow-up, surgery was not associated with significantly lower all-cause or prostate cancer-specific mortality compared to observation, with absolute differences of less than three percentage points.

The 19-year follow-up of PIVOT, published in the New England Journal of Medicine in 2017, confirmed this picture [9]. Surgery was associated with higher rates of adverse events than observation — particularly urinary incontinence and erectile dysfunction — but also with lower rates of treatment for local or biochemical disease progression. The key finding from longer follow-up: for men with high-risk localized cancer, surgery showed a signal toward mortality benefit. For men with low-risk cancer detected during the PSA screening era, the survival benefit was not statistically significant.

This context matters when comparing robotic to open surgery. If you are choosing between the two surgical approaches, you have already determined that surgery is appropriate for your cancer. The PIVOT data informs the first decision (surgery vs. active surveillance), not the second (robotic vs. open).

Cancer control: do the two approaches differ?

On oncologic outcomes — positive surgical margins, biochemical recurrence rates, and long-term cancer control — robotic and open prostatectomy are generally comparable when performed by experienced surgeons. Most large retrospective studies and systematic reviews show no meaningful difference in positive margin rates or 5- and 10-year biochemical recurrence-free survival.

For men with very high-risk disease (Gleason 9-10), the choice between surgery and radiation becomes more important than the choice between robotic and open surgery. A study published in JAMA involving William Aronson's institution examined outcomes in men with Gleason 9-10 prostate cancer treated with radical prostatectomy, external beam radiotherapy (EBRT), or EBRT combined with brachytherapy boost [10]. The EBRT plus brachytherapy group had substantially lower prostate cancer-specific mortality (3% at 5 years vs. 12% for prostatectomy and 13% for EBRT alone) and a much lower incidence of distant metastasis (8% vs. 24%). For this group of patients, the technique of surgery matters less than whether surgery is the right primary treatment modality at all.

What's changing

Robotic prostatectomy now accounts for the large majority of radical prostatectomies performed in the United States. Data from the CaPSURE registry, analyzed by Peter Carroll's group at UCSF, documented how rapidly treatment patterns shifted after robotic technology became widely available [3]. The shift happened faster than the evidence base could keep up with — most comparative studies are retrospective and subject to selection bias, meaning patients who underwent robotic surgery tended to have different baseline characteristics than those who had open surgery.

Current research is moving toward longer-term follow-up studies that compare functional outcomes at five or more years, and toward identifying which patient subgroups — by anatomy, tumor characteristics, or surgical risk — benefit most from one approach versus the other. Emerging data on focal therapy, nerve-sparing precision, and multiparametric MRI-guided surgical planning are also reshaping how the best surgical centers approach prostatectomy.

Overdiagnosis and patient selection

Peter Carroll co-authored a widely cited analysis of overdiagnosis and overtreatment of prostate cancer in European Urology, which examined the consequences of PSA screening-driven detection [4]. A meaningful proportion of prostate cancers detected through PSA screening are low-risk tumors that may never cause harm during a patient's lifetime. For those men, both robotic and open prostatectomy carry unnecessary risk of functional side effects. Active surveillance is a guideline-endorsed alternative for men with low-risk, localized disease, and a growing proportion of appropriately selected men are choosing it.

If you have been diagnosed with localized prostate cancer, the surgical technique question is secondary to the question of whether surgery is the right treatment for your specific cancer. A urologist experienced in both surveillance and surgery can help you work through that decision.

Questions to ask your surgeon

• What is your volume of robotic versus open prostatectomies per year, and what are your positive margin and continence rates?
• Is nerve-sparing surgery technically feasible for my tumor, based on the biopsy and imaging?
• Based on my Gleason score and PSA, is active surveillance a reasonable option I should consider first?
• What continence and erectile function outcomes should I realistically expect at 6, 12, and 24 months?
• Does my anatomy or any prior pelvic surgery affect whether robotic or open surgery is preferable in my case?

The bottom line

Robotic and open radical prostatectomy achieve comparable cancer control. Robotic surgery generally means less blood loss, a shorter hospital stay, and faster return to urinary continence — but long-term functional outcomes at two or more years are similar between skilled surgeons using either approach. For men with high-risk or very high-risk prostate cancer, the comparison between surgery and radiation is at least as important as the choice between surgical techniques. The right surgeon, doing the procedure they perform most frequently and with the best outcomes data, matters more than the platform they use.